Madrigal Pharmaceuticals, Inc.MDGLNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+16.5%
5Y CAGR+16.0%
Year-over-Year Change
Research and development spending
3Y CAGR
+16.5%/yr
vs +76.3%/yr prior
5Y CAGR
+16.0%/yr
Consistent
Acceleration
-59.8pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.1x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $388.52M | +64.1% |
| 2024 | $236.72M | -13.1% |
| 2023 | $272.35M | +11.0% |
| 2022 | $245.44M | +19.6% |
| 2021 | $205.16M | +11.0% |
| 2020 | $184.81M | +155.5% |
| 2019 | $72.32M | +184.9% |
| 2018 | $25.39M | +4.1% |
| 2017 | $24.39M | +53.1% |
| 2016 | $15.93M | - |